Abstract
Objective: To observe the clinical therapeutic effect of Shenmai Injection (SMI) in treating patients of congestive heart failure.Methods: Effect of 16 cases treated with either SMI or potassium magnesium aspartate was observed by randomized crossover method and compared.Results: By using SMI for 2 weeks, the patients’ left ventricular ejective fraction (LVEF) was increased from 29.5 ± 9.0 to 36.6 ± 10.2 (P < 0.05), the heart function of 68.75% patients was improved, no side effect or toxicity was observed. Potassium magnesium aspartate improved the heart function in 37. 50% patients only but showed no effect on LVEF.Conclusion: SMI is an effective and safe drug in treating patients with congestive heart failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
